BackChampions Oncology Overview

Champions Oncology Other Current Liabilities

Latest other current liabilities for CSBR: $230K.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$234000.00
↓ 87.79% YoYΔ $-1.68M vs prior year quarter

Peer trimmed avg / median

Loading

Champions Oncology Other Current Liabilities History

Loading

Champions Oncology vs. peers: Other Current Liabilities Comparison

Loading

Champions Oncology Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Champions Oncology (CSBR) FAQ

As of the most recent data (July 2026), CSBR shows a other current liabilities of $230K. That compares with $1.9M in the prior-year period — down 87.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CSBR's other current liabilities is now $230K (was $1.9M) — a 87.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Champions Oncology is outperforming or lagging.

Tracking CSBR's other current liabilities over time shows whether Champions Oncology is scaling, shrinking, or reshaping that part of the business. The current reading is $230K That compares with $1.9M in the prior-year period — down 87.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Champions Oncology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $230K) with ownership activity and broader fundamentals.

Champions Oncology's other current liabilities is $230K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.